• KineMed Inc., of Emeryville, Calif., received a Rapid Access to Intervention Development (RAID) grant from the National Institutes of Health for manufacturing, formulation and investigational new drug-enabling safety studies of FX-5A, an ApoA-I mimetic designed to reverse atherosclerosis and heart disease.